Diabetes lecture 2 Flashcards
Biguanide
Metformin
SGLT2 inhibitors
Canagliflozin
Dapagliflozin
Empagliflozin
GLP-1 receptor agonist
Exenatide
Liraglutide
Dulaglutide
Semaglutide (Ozempic (Sc) and Rybelsus (PO)
Sulfonylureas
Glyburide
Glipizide
Non-SU secretagogues
Repaglinide
DPP4 inhibitors
Sitagliptin
Saxagliptan
Linagliptin
TZDs
Pioglitazone
Metformin MOA
decreases hepatic glucose output, lowing fasting BG levels
enhances insulin sensitivity of both hepatic and muscle tissue
Metformin efficacy
lowers A1C 1-1.5%
weight loss
does not cause hypoglycemia
Metformin ADE
GI –> diarrhea, cramping, bloating
ER formulation –> less GI effects
Vitamin B 12 deficiency
Lactic acidosis -rare
Metformin (when to not use)
known hypersensitivity
surgical procedures
alcohol abuse
liver dysfunction
Significant renal disease
iodinated contrast media (GFR < 60)
Metformin and renal insufficiency
GFR > 60 –> ok
GFR 45-59 –> ok
GFR 30-44 –> metformin shouldn’t be started but can be continued
GFR < 30 –> do not use
Metformin dosing
usual dose is 1000 mg BID
500 or 850 mg po daily (with largest meal)
500mg po BID (with two largest meals)
if no GI effects, increase every 1-2 wks to max dose of 2000-25500mg/day
Metformin ER
given once daily
500, 750, 1000 ER tabs
titrate to 2000mg/daily
if taking 750 tab, max dose is 1500mg/day
Metformin monitoring
Counsel on adherence
A1c, renal function, vit B12
SMBG readings
take with meals
Advantages of metformin
Shown to reduce macrovascular complications in obese pts Other oral agents are not more effective in reducing HbA1c Does not cause hypoglycemia when used as monotherapy Does not cause weight gain (may be a/w weight loss of about 6 lb) Helps minimize weight gain with other agents Inexpensive Should see effects on BG within a week Comes in combination pills with many other oral agents
Disadvantages of metformin
GI adverse effects It is a large pill to swallow Metformin generally given BID Metformin ER given QD, but require multiple pills at the same time Risk of lactic acidosis - RARE Monitor for renal insufficiency Monitor for vit B12 deficiency
If A1c target is not achieved in about 3
months with metformin monotherapy,
add a second agent while: Re-emphasizing lifestyle measures Assessing adherence / access to medications Arranging routine follow-up
Second line therapy:
ASCVD
GLP and/or SGLT2 i
Second line therapy:
HF
SGLT2i
Second line therapy:
CKD
elevated UACR
SGLT2i preferred or GLP
Second line therapy:
CKD
no elevated UACR
GLP and/or SGLT2i
Agents to avoid in HF
Pioglitazone
Saxagliptan
Highest A1C efficacy
GLP-1 receptor
Weight loss
SGLT2 i
GLP-1
only one with risk of hypoglycemia
Sulfonylureas
Drugs that target fasting blood glucose
metformin
basal insulin
NPH insulin
Drugs that target post prandial BG levels
DPP-4 inhibitors
Exenatide
Regalinide
Prandial insulin
Drugs that have mixed BG level targets
Sulfonylureas long acting GLP-1 RA TDZ SGLT2i mixed insulins